{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:17:50Z","timestamp":1786994270433,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006733","name":"Indiana University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mp.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Modern Pathology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.modpat.2023.100151","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T12:07:16Z","timestamp":1678363636000},"page":"100151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6049-5293","authenticated-orcid":false,"given":"Liang","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lopez-Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumeal D.","family":"Whaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"De Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sammy","family":"Au","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongbin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Cimadamore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borivoj","family":"Golijanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory T.","family":"MacLennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeboye O.","family":"Osunkoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Montironi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaobo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.modpat.2023.100151_bib1","series-title":"Tumors of the Urinary Bladder","author":"Koss","year":"1975"},{"key":"10.1016\/j.modpat.2023.100151_bib2","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1097\/00000478-199612000-00007","article-title":"Papillary urothelial hyperplasia. A precursor to papillary neoplasms","volume":"20","author":"Taylor","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.modpat.2023.100151_bib3","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3109\/00313021003767322","article-title":"Papillary urothelial hyperplasia: relationship to urothelial neoplasms","volume":"42","author":"Readal","year":"2010","journal-title":"Pathology"},{"key":"10.1016\/j.modpat.2023.100151_bib4","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/1097-0215(20001120)89:6<514::AID-IJC8>3.0.CO;2-H","article-title":"Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer","volume":"89","author":"Chow","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.modpat.2023.100151_bib5","series-title":"Urologic Surgical Pathology","author":"Cheng","year":"2020"},{"key":"10.1016\/j.modpat.2023.100151_bib6","series-title":"AFIP atlas of tumor and non-tumor pathology: tumors of the kidney, bladder, and related urinary structures","author":"Eble","year":"2022"},{"key":"10.1016\/j.modpat.2023.100151_bib7","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/PAP.0000000000000308","article-title":"The genitourinary pathology society update on classification and grading of flat and papillary urothelial neoplasia with new reporting recommendations and approach to lesions with mixed and early patterns of neoplasia","volume":"28","author":"Amin","year":"2021","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.modpat.2023.100151_bib8","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1038\/s41379-022-01087-7","article-title":"Flat intraurothelial lesions of the urinary bladder-do hyperplasia, dysplasia, and atypia of unknown significance need to exist as diagnostic entities? and how to handle in routine clinical practice","volume":"35","author":"Paner","year":"2022","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2023.100151_bib9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00428-001-0577-6","article-title":"Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation","volume":"440","author":"Lopez-Beltran","year":"2002","journal-title":"Virchows Arch"},{"key":"10.1016\/j.modpat.2023.100151_bib10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.humpath.2021.04.001","article-title":"Molecular pathology of urothelial carcinoma","volume":"113","author":"Lopez-Beltran","year":"2021","journal-title":"Hum Pathol"},{"key":"10.1016\/j.modpat.2023.100151_bib11","series-title":"WHO Classification of Tumours of the Urinary System and Male Genital Organ","author":"Moch","year":"2016"},{"key":"10.1016\/j.modpat.2023.100151_bib12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.modpat.2023.100151_bib13","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2022.07.002","article-title":"The 2022 World Health Organization classification of tumors of the urinary system and male genital organs-part b: prostate and urinary tract tumors","volume":"82","author":"Netto","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.modpat.2023.100151_bib14","series-title":"WHO Classification of Tumours of the Urinary System and Male Genital Organs","year":"2022"},{"key":"10.1016\/j.modpat.2023.100151_bib15","article-title":"The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges","author":"Mohanty","year":"2022","journal-title":"Hum Pathol"},{"key":"10.1016\/j.modpat.2023.100151_bib16","article-title":"Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management","author":"Cheng","year":"2022","journal-title":"Hum Pathol"},{"key":"10.1016\/j.modpat.2023.100151_bib17","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.eururo.2020.07.002","article-title":"FGFR3 mutation status and FGFR3 expression in a large bladder cancer cohort treated by radical cystectomy: implications for anti-FGFR3 treatment?","volume":"78","author":"van Rhijn","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.modpat.2023.100151_bib18","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.eururo.2013.08.052","article-title":"Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome","volume":"65","author":"Allory","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.modpat.2023.100151_bib19","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1136\/jclinpath-2020-207115","article-title":"Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder","volume":"74","author":"Al-Obaidy","year":"2021","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.modpat.2023.100151_bib20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1158\/1541-7786.MCR-16-0003","article-title":"Understanding TERT promoter mutations: a common path to immortality","volume":"14","author":"Bell","year":"2016","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.modpat.2023.100151_bib21","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41585-018-0001-5","article-title":"Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis","volume":"15","author":"Gunes","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.modpat.2023.100151_bib22","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/his.13762","article-title":"Precursor lesions of the urinary bladder","volume":"74","author":"McKenney","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.modpat.2023.100151_bib23","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/modpathol.2009.28","article-title":"FGFR3 and TP53 mutation analysis in inverted urothelial papilloma: incidence and etiological considerations","volume":"22","author":"Lott","year":"2009","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2023.100151_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/his.12920","article-title":"Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change","volume":"69","author":"Cheng","year":"2016","journal-title":"Histopathology"},{"key":"10.1016\/j.modpat.2023.100151_bib25","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1038\/s41379-021-00776-z","article-title":"Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications","volume":"34","author":"Cheng","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.modpat.2023.100151_bib26","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.eururo.2016.12.008","article-title":"TERT promoter mutations occur frequently in urothelial papilloma and papillary urothelial neoplasm of low malignant potential","volume":"71","author":"Cheng","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.modpat.2023.100151_bib27","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1586\/era.10.73","article-title":"The origins of urothelial carcinoma","volume":"10","author":"Cheng","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.modpat.2023.100151_bib28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/PAT.0b013e32835f6169","article-title":"Premalignant lesions of the urinary bladder","volume":"45","author":"Samaratunga","year":"2013","journal-title":"Pathology"},{"key":"10.1016\/j.modpat.2023.100151_bib29","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.mpdhp.2013.08.003","article-title":"Pathology of flat bladder lesions with emphasis on putative precursors","volume":"19","author":"Cheng","year":"2013","journal-title":"Diagn Histopathol"},{"key":"10.1016\/j.modpat.2023.100151_bib30","doi-asserted-by":"crossref","first-page":"853","DOI":"10.5858\/arpa.2019-0005-OA","article-title":"Urothelial proliferation of unknown malignant potential involving the bladder: histopathologic features and risk of progression in de novo cases and cases with prior neoplasia","volume":"144","author":"Lowenthal","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.modpat.2023.100151_bib31","article-title":"Integrative clinical and genomic characterization of MTAP-deficient metastatic urothelial cancer","author":"Alhalabi","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.modpat.2023.100151_bib32","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1038\/s41467-021-25894-9","article-title":"9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy","volume":"12","author":"Han","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.modpat.2023.100151_bib33","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1038\/s41467-018-06890-y","article-title":"Targeting IFN\u03b1 to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance","volume":"9","author":"Liang","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.modpat.2023.100151_bib34","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1158\/1078-0432.CCR-17-3008","article-title":"Prevalent homozygous deletions of type I interferon and defensin genes in human cancers associate with immunotherapy resistance","volume":"24","author":"Ye","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.modpat.2023.100151_bib35","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.modpat.2023.100151_bib36","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2217\/fon.09.50","article-title":"Molecular determinants of tumor recurrence in the urinary bladder","volume":"5","author":"Cheng","year":"2009","journal-title":"Future Oncol"},{"key":"10.1016\/j.modpat.2023.100151_bib37","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.humpath.2010.07.007","article-title":"Bladder cancer: translating molecular genetic insights into clinical practice","volume":"42","author":"Cheng","year":"2011","journal-title":"Hum Pathol"},{"key":"10.1016\/j.modpat.2023.100151_bib38","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.eururo.2013.08.057","article-title":"Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine","volume":"65","author":"Hurst","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.modpat.2023.100151_bib39","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00428-014-1608-4","article-title":"Telomerase promoter mutations in cancer: an emerging molecular biomarker?","volume":"465","author":"Vinagre","year":"2014","journal-title":"Virchows Arch"},{"key":"10.1016\/j.modpat.2023.100151_bib40","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1126\/science.1260200","article-title":"Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer","volume":"347","author":"Borah","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.modpat.2023.100151_bib41","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.4161\/cc.24662","article-title":"Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma","volume":"12","author":"Liu","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.modpat.2023.100151_bib42","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1073\/pnas.1303607110","article-title":"TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal","volume":"110","author":"Killela","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.modpat.2023.100151_bib43","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/path.1202","article-title":"Frequent FGFR3 mutations in urothelial papilloma","volume":"198","author":"van Rhijn","year":"2002","journal-title":"J\u00a0Pathol"}],"container-title":["Modern Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089339522300056X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089339522300056X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T01:23:17Z","timestamp":1760232197000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089339522300056X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S089339522300056X"],"URL":"https:\/\/doi.org\/10.1016\/j.modpat.2023.100151","relation":{},"ISSN":["0893-3952"],"issn-type":[{"value":"0893-3952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder","name":"articletitle","label":"Article Title"},{"value":"Modern Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.modpat.2023.100151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100151"}}